Supplemental material
Journal of Dermatological Treatment
Volume 33, 2022 - Issue 1
Articles
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials
S. Barbarota Service de Dermatologie, Centre Hospitalier Universitaire de Nantes, Nantes, France
https://orcid.org/0000-0002-6629-9100View further author information
https://orcid.org/0000-0002-6629-9100View further author information, A. Wollenbergb Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germanyhttps://orcid.org/0000-0003-0177-8722View further author information
https://orcid.org/0000-0003-0177-8722View further author information, J. I. Silverbergc Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USAhttps://orcid.org/0000-0003-3686-7805View further author information
https://orcid.org/0000-0003-3686-7805View further author information, M. Deleurand Department of Dermatology, Aarhus University Hospital, Aarhus, Denmarkhttps://orcid.org/0000-0003-0593-9925View further author information
https://orcid.org/0000-0003-0593-9925View further author information, G. Pellacanie Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italyhttps://orcid.org/0000-0002-7222-2951View further author information
https://orcid.org/0000-0002-7222-2951View further author information, J. C. Armario-Hitaf Service of Dermatology, University Hospital of Puerto Real, University of Cádiz, Cádiz, Spainhttps://orcid.org/0000-0002-9919-0486View further author information
https://orcid.org/0000-0002-9919-0486View further author information, , , , , & A. B. Rossii Sanofi Genzyme, Cambridge, MA, USACorrespondence[email protected]
https://orcid.org/0000-0001-5345-678XView further author information
https://orcid.org/0000-0001-5345-678XView further author information show all